Follow us on our LinkedIn page for the latest updates from Immitra Bio.
Immitra Bio has been selected for the 2026 Venture Leaders Biotech program, joining the Swiss National Startup Team for a Boston roadshow from May 31 to June 5.
Read moreOur CEO (Jan Nelis) will attend Bio€quity Europe 2026, taking place from May 4–6 in Prague, Czech Republic. Now in its 26th edition, Bio€quity Europe is one of the leading gatherings of the European biotech investment community, bringing together CEOs, venture capital investors, and pharmaceutical partners to discuss strategy, financing, and the future of the industry. The conference provides a platform for emerging biotechnology companies to engage with global investors, explore strategic partnerships, and position their innovations within the evolving European life sciences landscape.
Learn moreOur CSO (Amir Taheri) will participate in Swiss Biotech Day 2026, one of Europe’s leading biotechnology conferences, taking place from May 4–5 at the Congress Center Basel. The event brings together more than 3,000 life sciences professionals from over 40 countries, including startups, industry leaders, and investors. The conference provides a platform to connect with partners, explore advances in R&D and biotechnology, and engage with the global life sciences ecosystem through networking, pitching sessions, and one-to-one meetings.
Learn moreGebert Rüf Stiftung supports high-potential businesses from the Venture Kick program with the aim of substantially accelerating their market entry. The funding line is calling for top talents with convincing applications of how a research & development or design boost can speed up a successful market penetration of their deeptech business.
Read moreImmitra Bio is featured in PME, outlining its approach to overcoming one of the biggest bottlenecks in gene therapy: scalability. Today’s treatments are largely developed ex-vivo, requiring complex cell manipulation, chemotherapy, and highly personalized processes that can cost hundreds of thousands per patient and remain out of reach for most. Immitra Bio is developing an in-vivo alternative, aiming to replace months-long procedures with a single injection capable of correcting genetic defects directly in the body.
Read moreImmitra Bio received Venture Kick support to advance an in-vivo gene editing platform for blood disorders, aiming to make curative therapies faster, safer, and more scalable.
Read moreImmitra Bio was selected to present at the DeepTech Investor Summit 2026, showcasing its in-vivo gene editing platform designed to make genetic therapies safer, simpler, and scalable.
Learn moreForbes 30 Under 30 highlights influential personalities in Switzerland, Germany, and Austria who are making a positive impact across business and society.
Read moreImmitra Bio has been awarded a seed loan from the FONGIT Innovation Fund to advance its genetic medicine platform. The funding supports the development of scalable therapies for rare diseases and strengthens collaboration with Geneva’s research ecosystem.
Read more